Sartor O, Appukkuttan S, Weiss J, et al. - This study was carried out to assess practice patterns and treatment outcomes in patients with metastatic castration‐resistant prostate cancer (mCRPC) treated at a community practice (CP) compared with those treated at an academic center (AC). Between January 2014 and June 2017, researchers conducted a retrospective review including 200 adult mCRPC patients receiving radium‐223. They also performed a subset analysis of OS based on the number of radium‐223 doses and on sequencing of radium‐223 either before or after chemotherapy. The results demonstrate that most individuals received radium‐223 concurrently with abiraterone acetate or enzalutamide and were able to complete 5–6 doses of radium‐223. No survival differences between patients treated in ACs vs CPs were found, despite differences in the populations and treatment patterns. There is a need for additional real‐world data to validate these findings.